Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

71%

5 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 3

3(42.9%)

Phase 4

2(28.6%)

Phase 2

1(14.3%)

N/A

1(14.3%)

7Total

Phase 3(3)

Phase 4(2)

Phase 2(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04951856Phase 4Active Not Recruiting

Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI

Role: collaborator

NCT06215378Phase 3Recruiting

Antagonization of Heparin With Protamine Sulfate After TAVI

Role: collaborator

NCT06091514Not ApplicableNot Yet Recruiting

Connected Cardiology to Control Cardiac Rythm

Role: collaborator

NCT03273322Phase 2Completed

Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure

Role: collaborator

NCT02664649Phase 3Completed

Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic Stenosis

Role: collaborator

NCT02617290Phase 3Completed

Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting

Role: collaborator

NCT02463110Phase 4Terminated

Acute Myocardial Necrosis and Depression: Antiplatelet Effect of Reuptake Inhibition of Serotonin

Role: collaborator

All 7 trials loaded